About i2o Therapeutics
i2o Therapeutics is a company based in Boston (United States) founded in 2019 by Samir Mitragotri and Ravi Srinivasan.. i2o Therapeutics has raised $53.5 million across 6 funding rounds from investors including Colorcon, Sanofi Ventures and T1D Fund. The company has 6 employees as of December 31, 2021. i2o Therapeutics operates in a competitive market with competitors including Lyndra, Biora Therapeutics, Cure Pharmaceutical, Cingulate and OnDosis, among others.
- Headquarter Boston, United States
- Employees 6 as on 31 Dec, 2021
- Founders Samir Mitragotri, Ravi Srinivasan
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name I2o Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$53.5 M (USD)
in 6 rounds
-
Latest Funding Round
$3.5 M (USD), Series A
Oct 18, 2023
-
Investors
Colorcon
& 2 more
-
Employee Count
6
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of i2o Therapeutics
i2o Therapeutics has successfully raised a total of $53.5M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $3.5 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Series A — $3.5M
-
First Round
First Round
(23 Mar 2020)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Series A - i2o Therapeutics | Valuation |
investors |
|
| Aug, 2023 | Amount | Series A - i2o Therapeutics | Valuation |
investors |
|
| Dec, 2020 | Amount | Seed - i2o Therapeutics | Valuation | Colorcon |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in i2o Therapeutics
i2o Therapeutics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Colorcon, Sanofi Ventures and T1D Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location | |
|
Companies developing T1D products are funded through venture philanthropy.
|
Founded Year | Domain | Location | |
|
Developer of specialty excipients and corporate-backed venture capital fund focused on healthcare startups
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by i2o Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - i2o Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
I2o Therapeutics Comparisons
Competitors of i2o Therapeutics
i2o Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Lyndra, Biora Therapeutics, Cure Pharmaceutical, Cingulate and OnDosis, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Innovates long-acting oral therapies to simplify patient medication regimens.
|
|
| domain | founded_year | HQ Location |
Smart pills are developed for targeted gastrointestinal drug delivery.
|
|
| domain | founded_year | HQ Location |
Oral thin film-based drug delivery systems are developed.
|
|
| domain | founded_year | HQ Location |
Cingulate is focused on developing treatments for ADHD and anxiety.
|
|
| domain | founded_year | HQ Location |
Oral drug delivery systems for individualized micro-unit dosing are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on I2o Therapeutics
Frequently Asked Questions about i2o Therapeutics
When was i2o Therapeutics founded?
i2o Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is i2o Therapeutics located?
i2o Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is i2o Therapeutics a funded company?
i2o Therapeutics is a funded company, having raised a total of $53.5M across 6 funding rounds to date.
How many employees does i2o Therapeutics have?
As of Dec 31, 2021, the latest employee count at i2o Therapeutics is 6.
What does i2o Therapeutics do?
i2o Therapeutics was founded in 2019 in Boston, United States, as a biotechnology firm focused on drug delivery systems. A liquid platform is utilized by the company to enable oral administration of therapeutics. Drug molecules are protected within this technology, while permeation across the epithelial lining is enhanced for better absorption. Operations center on developing this solution for pharmaceutical applications in the oral delivery sector.
Who are the top competitors of i2o Therapeutics?
i2o Therapeutics's top competitors include Cingulate, Cure Pharmaceutical and PLx Pharma.
Who are i2o Therapeutics's investors?
i2o Therapeutics has 3 investors. Key investors include Colorcon, Sanofi Ventures, and T1D Fund.